

Oncology Today with Dr Neil Love: EGFR Mutation-Positive Non-Small Cell Lung Cancer Edition (Audio Interview)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following disease-free survival outcomes was reported from the Phase III ADAURA trial evaluating osimertinib as adjuvant therapy after complete tumor resection for patients with Stage IB to IIIA non-small cell lung cancer (NSCLC) with EGFR mutations?
 - a. Statistically significant improvement over placebo for patients with Stage IB to IIIA disease
 - b. Statistically significant improvement over placebo for patients with Stage II and IIIA but not Stage IB disease
 - c. No statistically significant improvement over placebo in any subgroup
2. The investigational agent mobocertinib (TAK-788) has shown promising activity in the treatment of metastatic NSCLC with which type of EGFR mutation?
 - a. Exon 19 deletion
 - b. Exon 20 insertion mutation
 - c. Exon 21 mutation
3. Which of the following drug types best describes the mechanism of action of the novel agent patritumab deruxtecan (U3-1402)?
 - a. EGFR tyrosine kinase inhibitor
 - b. HER3-directed antibody-drug conjugate
 - c. MET inhibitor
4. Patients with NSCLC with EGFR exon 20 insertions are more likely to experience skin toxicity and infusion-related reactions with which of the following agents?
 - a. Amivantamab
 - b. Mobocertinib